Covidien unveils ClosureFast ablation study results

January 3, 2013 by MassDevice staff

Covidien releases 5- year results of its ClosureFast Long-Term European Multi-Center Study in treating patients with chronic venous insufficiency.

Covidien logo

Covidien (NYSE:COV) unveiled the results of its ClosureFast Long-Term European Multi-Center Study, which evaluated 5-year outcomes of the medical device maker's radiofrequency ablation therapy in patients with chronic venous insufficiency.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.


Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp